AACR 2026 Poster 2177

Characterization of a Panel of PDX Models Derived from PARP Inhibitors Pretreated Breast and Ovarian Cancer Patients for Therapeutic Evaluation

Qingzhi Liu, Jinxin Wang, Leilei Chen, Wubin Qian, Likun Zhang, Ludovic Bourre, Jessie J.J. Wang

Discover how clinically relevant PDX models enable deeper insights into PARP inhibitor resistance and therapeutic response.

Resistance to PARP inhibitors remains a major challenge in breast and ovarian cancers. This study presents a panel of PDX models derived from PARPi-pretreated patients, providing a translational platform to evaluate therapeutic efficacy and uncover resistance mechanisms. By integrating molecular characterization with in vivo response data, these models support more informed decision-making for next-generation therapies and combinations.

Download this Poster to Discover:

• Evaluate PARPi response in clinically relevant models: Assess olaparib, niraparib, and talazoparib efficacy across breast and ovarian PDX models.
  
  
• Understand resistance mechanisms: Explore genomic and molecular features including BRCA status, HRD scores, and MDM2/MDM4 alterations.
  
  
• Compare tumor growth and treatment response: Analyze variability in tumor progression and drug sensitivity across models.
  
  
• Link biomarkers to therapeutic outcomes: Identify molecular drivers associated with reduced PARPi sensitivity.
  
  
• Support translational decision-making: Leverage clinically derived models to guide combination strategies and next-generation therapies.

Download the Poster Now!